Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1378-1386

  LeBeau, Aaron M ^a   Brennen, W Nathaniel ^a   Aggarwal, Saurabh ^b   Denmeade, Samuel R ^a,b,c,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Johns Hopkins University   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELITTIN; PRODRUG; PROMELITTIN; PROTOXIN; SEPRASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL STRAIN LNCAP; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; FIBROBLASTS; GELATINASES; HUMANS; MALE; MELITTEN; MEMBRANE PROTEINS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN ENGINEERING; PROTEIN PRECURSORS; SERINE ENDOPEPTIDASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66849125864     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1170     Document Type: Article

References (37)

1. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659 (Pubitemid 17052899)
2. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336 (Pubitemid 121001258)
3. Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990;348:699-704. (Pubitemid 120015135)
4. Brown LF, Guidi AJ, Schnitt SJ, et al. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Clin Cancer Res 1999;5:1041-1056 (Pubitemid 29233218)
5. Haslam SZ, Woodward TL. Host microenvironment in breast cancer development: epithelial-cell-stromal-cell interactions and steroid hormone action in normal and cancerous mammary gland. Breast Cancer Res 2003;5:208-215
6. Iozzo RV. Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab Invest 1995;73:157-160
7. Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A 1990;87:7235-7239 (Pubitemid 20325241)
8. Aoyama A, Chen WT. A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci U S A 1990;87:8296-8300 (Pubitemid 120016392)
9. Piñeiro-Sánchez ML, Goldstein LA, Dodt J, et al. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem 1997;272:7595-7601 (Pubitemid 27137306)
10. Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein α, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A 1994;91:5657-5661 (Pubitemid 24174387)
11. Rettig WJ, Garin-Chesa P, Beresford HR, Oettgen HF, Melamed MR, Old LJ. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A 1988;85:3110-3114 (Pubitemid 18138165)
12. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 2002;8:2912-2923 (Pubitemid 35025739)
13. Cheng JD, Dunbrack RL, Jr., Valianou M, Rogatko A, Alpaugh RK, Weiner LM. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 2002;62:4767-4772 (Pubitemid 34898606)
14. Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M. Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 2008;9:201.
15. Kelly T. Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Update 2005;8:51-58 (Pubitemid 40797956)
16. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999;274:36505-36512 (Pubitemid 30005259)
17. Aggarwal S, Brennen WN, Kole TP, et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry 2008;47:1076-1086
18. Terwilliger TC, Eisenberg D. The structure of melittin. J Biol Chem 1982;257:6016-6022
19. Unger T, Oren Z, Shai Y. The effect of cyclization on magainin 2 and melittin analogues on the structure, function, and model membranes interactions: implications to their mode of action. Biochemistry 2001;40:6388-6397 (Pubitemid 32472728)
20. Werkmeister JA, Hewish DR, Kirkpatrick A, Rivett DE. Sequence requirements for the activity of membrane active peptides. J Peptide Res 2002;60:232-238 (Pubitemid 35155432)
21. Hristova K, Dempsey CE, White SH. Structure, location and lipid perturbations of melittin at the membrane interface. Biophysical J 2001;80:801-811 (Pubitemid 32128331)
22. Kreil G, Haiml L, Suchanek G. Stepwise cleavage of the pro part of promelittin by dipeptidylpeptidase 4. Eur J Biochem 1980;111:49-58.
23. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007;99:376-385 (Pubitemid 47073481)
24. Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res 2006;66:9171-9177 (Pubitemid 44521137)
25. Edosada CY, Quan C, Wiesmann C, et al. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity. J Biol Chem 2006;281:7437-7444 (Pubitemid 43847515)
26. Ostermann E, Garin-Chesa P, Heider KH, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 2008;14:4584-4592
27. Verel I, Heider KH, Siegmund M, et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearinghead-and-neck cancer xenografts. Int J Cancer 2002;99:396-402. (Pubitemid 34495853)
28. Tahtis K, Lee FT, Wheatley JM, et al. Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model. Mol Cancer Ther 2003;2:729-737
29. Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003;9:1639-1647 (Pubitemid 36554586)
30. Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie 2003;26:44-48
31. Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res 2004;64:5471-5480 (Pubitemid 39006571)
32. Aertgeerts K, Levin I, Shi L, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein α. J Biol Chem 2005;280:19441-19444 (Pubitemid 41379462)
33. Wolf BB, Quan C, Tran T, Wiesmann C, Sutherlin D. On the edge of validation - cancer protease fibroblast activation protein. Mini-reviews in Med Chem 2008;8:719-727.
34. Ariga N, Sato E, Ohuchi N, Nagura H, Ohtani H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 2001;95:67-72. (Pubitemid 32118615)
35. Denmeade SR, Jakobsen CM, Janssen S, et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003;95:990-1000. (Pubitemid 36896716)
36. Janssen S, Rosen DM, Ricklis RM, et al. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate 2006;66:358-368 (Pubitemid 43346946)
37. Mhaka A, Gady AM, Rosen DM, Lo KM, Gillies SD, Denmeade SR. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 2004;3:551-558 (Pubitemid 41351127)